Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DTBZ PET for Differential Diagnosis of Parkinson's Disease and Parkinsonism
NCT01824056Phase 2Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Aug 2010
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Florbenazine F-18 in Parkinson's disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and 1 more, sponsored by Chang Gung Memorial Hospital. Primary endpoint: Sensitivity and Specificity of 18F-DTBZ PET at 3 years. Started Aug 2010; status: completed.
02
Drugs
Florbenazine F-18
03
Conditions
Parkinson's disease (PD)multiple system atrophy (MSA)progressive supranuclear palsy (PSP)corticobasal degeneration (CBD)
Beyond the preview
Go deeper on NCT01824056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01824056.